Pharmacology, Toxicology and Pharmaceutical Science
Dry Powder Inhaler
100%
Nanoparticle
64%
Microparticle
42%
Cell Culture
38%
Pulmonary Surfactant
36%
Pulmonary Hypertension
33%
Nanomedicine
31%
Phospholipid
30%
Cystic Fibrosis
26%
Pulmonary Drug Delivery
25%
Dipalmitoylphosphatidylcholine
24%
Powder Formulation
24%
Lung Cancer
22%
Nanocarrier
20%
Lung Disease
20%
Antibiotic Agent
18%
Paclitaxel
17%
Trehalose
17%
Cell Viability
17%
Lactose
16%
Transcription Factor Nrf2
16%
Differential Scanning Calorimetry
15%
Scanning Electron Microscopy
15%
Formoterol
14%
Mannitol
14%
Drug Release
13%
Disease
12%
Rho Kinase Inhibitor
12%
Dipalmitoylphosphatidylglycerol
11%
Polyglactin
11%
Respiratory Tract Disease
11%
Glycopeptide
11%
Fourier Transform Infrared Spectroscopy
11%
Simvastatin
10%
Rho Kinase
10%
Antibiotics
10%
Dosage Forms
10%
Bronchiolitis Obliterans
9%
Pharmaceutics
9%
Carnitine
9%
Raman Microscopy
9%
Chronic Obstructive Lung Disease
9%
Side Effect
8%
Peptides and Proteins
8%
Tobramycin
8%
Controlled Release
7%
Polypeptide
7%
Salbutamol Sulfate
7%
Cromoglicic Acid
7%
Ipratropium Bromide
7%
Keyphrases
Lung Transplantation
19%
Dry Powder Inhaler
18%
Cystic Fibrosis
14%
Aerosol Dispersion
14%
Lung Surfactant
14%
Pulmonary Hypertension
12%
Physicochemical Characterization
12%
Cellular Studies
10%
Nanoparticles
10%
Inhalable
10%
Advanced Lung Disease
10%
Aerosol Delivery
9%
Inhalation Aerosols
9%
Pulmonary Inhalation
9%
Nanomedicine
9%
Lung Cancer
9%
Paclitaxel
9%
Dispersion Study
9%
Phosphatidylglycerol
9%
Multifunctional Particles
9%
High Performance
9%
Lung Delivery
9%
RhoA
9%
Confidence Interval
7%
Hazard Ratio
7%
Dry Powder
7%
Fasudil
7%
Microparticulate
6%
Nanoparticulate
6%
Spray-dried Microparticles
6%
Bronchiolitis Obliterans Syndrome
6%
Transplantation
6%
Dry Powder Inhaler Formulation
6%
Respirable
6%
Nanocarriers
6%
Rho Kinase Inhibitor
6%
Co-spray
6%
Right Heart Catheterization
5%
Inhalation Delivery
5%
Targeted Delivery
5%
Air-interface Culture
5%
Medicine and Dentistry
Lung Transplantation
50%
Cystic Fibrosis
35%
Patient with Cystic Fibrosis
17%
Hazard Ratio
11%
Pulmonary Hypertension
11%
Proportional Hazards Model
10%
Advanced Lung Disease
10%
Human Leukocyte Antigen
9%
Bronchiolitis Obliterans
7%
Pediatrics
7%
Drug Delivery System
6%
Chemical Imaging
6%
Lung Artery Pressure
5%
Immunosuppressive Treatment
5%